IL274162A - Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof - Google Patents
Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereofInfo
- Publication number
- IL274162A IL274162A IL274162A IL27416220A IL274162A IL 274162 A IL274162 A IL 274162A IL 274162 A IL274162 A IL 274162A IL 27416220 A IL27416220 A IL 27416220A IL 274162 A IL274162 A IL 274162A
- Authority
- IL
- Israel
- Prior art keywords
- selenogalactoside
- compounds
- treatment
- insulin resistance
- systemic insulin
- Prior art date
Links
- 206010022489 Insulin Resistance Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579343P | 2017-10-31 | 2017-10-31 | |
| PCT/US2018/032321 WO2019089080A1 (en) | 2017-10-31 | 2018-05-11 | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL274162A true IL274162A (en) | 2020-06-30 |
Family
ID=66332241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL274162A IL274162A (en) | 2017-10-31 | 2020-04-23 | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3707149A1 (en) |
| JP (1) | JP2021501180A (en) |
| KR (1) | KR20200081443A (en) |
| CN (1) | CN111527097A (en) |
| AU (1) | AU2018361991A1 (en) |
| CA (1) | CA3080128A1 (en) |
| IL (1) | IL274162A (en) |
| WO (1) | WO2019089080A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3475706B1 (en) * | 2016-06-27 | 2021-08-11 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | CANCER TREATMENT BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| CN113711036B (en) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | Anti-GAL3 antibodies and uses thereof |
| ES2974680T3 (en) | 2019-08-09 | 2024-07-01 | Idorsia Pharmaceuticals Ltd | Derivatives of (2-acetamidyl)thio-beta-D-galactopyranosides |
| US12404295B2 (en) | 2019-08-09 | 2025-09-02 | Idorsia Pharmaceuticals Ltd | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| UA128909C2 (en) | 2019-08-15 | 2024-11-20 | Ідорсія Фармасьютікалз Лтд | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES |
| PH12022550436A1 (en) * | 2019-08-29 | 2022-12-19 | Idorsia Pharmaceuticals Ltd | Alpha-d-galactopyranoside derivatives |
| JP7835441B2 (en) * | 2019-12-06 | 2026-03-25 | トゥルーバインディング，インコーポレイテッド | Antibodies that interfere with the interaction between GAL3 and insulin receptors or integrins, and methods for using them. |
| CN116157151A (en) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | Methods of treating inflammatory diseases by blocking galectin-3 |
| AU2021356076A1 (en) | 2020-10-06 | 2023-06-08 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| IL302421A (en) | 2020-11-02 | 2023-06-01 | Idorsia Pharmaceuticals Ltd | 2-Hydroxycycloalkane-1-carbamoyl compounds inhibit galectin-3 |
| CN112190590A (en) * | 2020-11-06 | 2021-01-08 | 牡丹江医学院 | Selenium nucleoside for treating atherosclerosis and pharmaceutical composition thereof |
| JP7844491B2 (en) | 2021-02-09 | 2026-04-13 | イドルシア・ファーマシューティカルズ・リミテッド | Hydroxyheterocycloalkane-carbamoyl derivatives |
| EP4301748B1 (en) | 2021-03-03 | 2025-05-07 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
| JP1763359S (en) | 2023-09-08 | 2024-02-13 | ||
| WO2025084276A1 (en) * | 2023-10-16 | 2025-04-24 | Ｃｙｎ－Ｋバイオ株式会社 | Treatment of obesity |
| JP1779661S (en) | 2024-05-09 | 2024-09-11 | ||
| JP1779660S (en) | 2024-05-09 | 2024-09-11 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3250581B1 (en) * | 2015-01-30 | 2021-01-20 | Galecto Biotech AB | Alpha-d-galactoside inhibitors of galectins |
| CN105318222B (en) * | 2015-11-13 | 2018-07-27 | 南通亚泰蜡业工艺品有限公司 | Fountain electric candle |
| JP7086008B2 (en) * | 2016-03-04 | 2022-06-17 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー | Serenogalactoside compounds and their use for the prevention and treatment of galactin-related diseases |
-
2018
- 2018-05-11 JP JP2020524157A patent/JP2021501180A/en active Pending
- 2018-05-11 AU AU2018361991A patent/AU2018361991A1/en not_active Abandoned
- 2018-05-11 CA CA3080128A patent/CA3080128A1/en active Pending
- 2018-05-11 KR KR1020207015450A patent/KR20200081443A/en not_active Withdrawn
- 2018-05-11 WO PCT/US2018/032321 patent/WO2019089080A1/en not_active Ceased
- 2018-05-11 CN CN201880083771.8A patent/CN111527097A/en active Pending
- 2018-05-11 EP EP18874558.2A patent/EP3707149A1/en not_active Withdrawn
-
2020
- 2020-04-23 IL IL274162A patent/IL274162A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3707149A1 (en) | 2020-09-16 |
| CA3080128A1 (en) | 2019-05-09 |
| WO2019089080A9 (en) | 2020-07-23 |
| WO2019089080A1 (en) | 2019-05-09 |
| KR20200081443A (en) | 2020-07-07 |
| CN111527097A (en) | 2020-08-11 |
| JP2021501180A (en) | 2021-01-14 |
| AU2018361991A1 (en) | 2020-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| IL259751B (en) | Polycyclic compounds and use thereof in the treatment of immune disorders | |
| IL290754A (en) | Use of pridopidine for the treatment of anxiety and depression | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| IL290150A (en) | Compositions and methods for the treatment of chronic pain | |
| PT3227237T (en) | Device and use thereof for the uv treatment of fluids | |
| IL257173A (en) | Novel insulin derivatives and the medical uses hereof | |
| IL272097A (en) | Compounds for the prevention and treatment of medical disorders and uses thereof | |
| GB201715194D0 (en) | Compounds and their therapeutic use | |
| IL281585B (en) | Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| GB201617064D0 (en) | Compounds and their therapeutic use | |
| GB201813312D0 (en) | Compounds and their therapeutic use | |
| IL275349A (en) | Use of hm4di in the treatment of seizure disorders | |
| SI3452465T1 (en) | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | |
| IL249485B (en) | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated with an accumulation of misfolded proteins | |
| IL274838A (en) | Use of mir101 or mir128 in the treatment of seizure disorders | |
| IL273863B1 (en) | Device for use in the treatment of hemorrhoids | |
| IL271878A (en) | Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions | |
| GB201915641D0 (en) | Glucose-responsive insulin analogs and methods of use thereof | |
| PL3148990T3 (en) | Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | |
| GB201819430D0 (en) | Therapeutic compounds, nanoparticles and uses thereof | |
| PT3148990T (en) | Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation | |
| HK40009960A (en) | Use of pridopidine for the treatment of anxiety and depression | |
| PL3370727T3 (en) | Non-bioconvertible c3-substituted pregnenolone derivatives for use in the treatment of substance use disorders |